Shire’s “Overweight” Rating Reaffirmed at Morgan Stanley (SHP)
Shire (LON:SHP)‘s stock had its “overweight” rating restated by equities research analysts at Morgan Stanley in a research note issued to investors on Tuesday, StockRatingsNetwork.com reports. They currently have a GBX 2,750 ($43.00) price objective on the stock. Morgan Stanley’s target price indicates a potential upside of 11.52% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. raised their price target on shares of Shire (LON:SHP) from GBX 2,600 ($40.65) to GBX 2,900 ($45.34) in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at BNP Paribas reiterated an “outperform” rating on shares of Shire (LON:SHP) in a research note to investors on Tuesday, September 3rd. They now have a GBX 2,500 ($39.09) price target on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Shire (LON:SHP) in a research note to investors on Tuesday, September 3rd. They now have a GBX 2,660 ($41.59) price target on the stock.
One analyst has rated the stock with a sell rating, six have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of GBX 2,146.11 ($33.55).
Shire (LON:SHP) traded up 0.98% on Tuesday, hitting GBX 2466.00. The stock had a trading volume of 1,722,025 shares. Shire has a 52-week low of GBX 1682.00 and a 52-week high of GBX 2482.00. The stock’s 50-day moving average is GBX 2387. and its 200-day moving average is GBX 2144.12. The company’s market cap is £13.553 billion.
Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.